Second-generation antipsychotic exposure and metabolic-related disorders in patients with schizophrenia: An observational pharmacoepidemiology study from 1988 to 2002

Journal of Clinical Psychopharmacology

Volumn 27, Issue 1, 2007, Pages 46-51

  Reist, Christopher ^a,b,c   Mintz, Jim ^b   Albers, Lawrence J ^a   Jamal, M Mazen ^a   Szabo, Sandor ^a   Ozdemir, Vural ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA LONG BEACH HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMMUNITY HOSPITAL; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; HEALTH CARE POLICY; HOSPITAL PATIENT; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT CARE; PREVALENCE; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; DIABETES MELLITUS; HOSPITALIZATION; HUMANS; LONGITUDINAL STUDIES; MIDDLE AGED; OBESITY; PREVALENCE; SCHIZOPHRENIA;

EID: 33846244981     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31802e5126     Document Type: Article

References (20)

1. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry. 2004;161:1334-1349.
2. Newman SC, Bland RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry. 1991;36:239-245.
3. Casey DE, Haupt DW, Newcomer JW, et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry. 2004;65(suppl 7):4-18.
4. De Hert MA, van Winkel R, Van Eyck D, et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res. 2006;83:87-93.
5. American Diabetes Association Consensus development conference on antipsychotic drugs and obesity (Consensus Statement). Diabetes Care. 2004;27:596-601.
6. Agency for Healthcare Research and Quality. Healthcare Cost and Utilization Project. Nationwide Inpatient Sample. Rockville, MD: AHRQ. Available at: htttp://www.ahrq.gov/data/hcup/. Accessed September 29, 2006.
7. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999-2000. JAMA. 2002;288:1723-1727.
8. Allison DB, Fontaine KR, Heo M, et al. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry. 1999;60:215-220.
9. Goff DC, Sullivan LM, McEvoy JP, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res. 2005;80:45-53.
10. Oguma Y, Sesso HD, Paffenbarger RS, et al. Weight change and risk of developing type 2 diabetes. Obes Res. 2005;13:945-951.
11. McIntyre RS, McCann SM, Kennedy SH. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry. 2001;46:273-281.
12. Sernyak MJ, Leslie DL, Alarcon RD, et al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry. 2002;159:561-566.
13. Koro CE, Fedder DO, L'Italien GJ, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ. 2002;325:243-245.
14. Cohen D, Dekker JJ, Peen J, et al. Prevalence of diabetes mellitus in chronic schizophrenic inpatients in relation to long-term antipsychotic treatment. Eur Neuropsychopharmacol. 2006;16:187-194.
15. Henderson DC, Cagliero E, Gran C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry. 2000;157:975-981.
16. Citrome L, Jaffe A, Levine J, et al. Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Psychiatric Serv. 2004;55:1001-1006.
17. Leslie DL, Rosenheck RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry. 2004;161:1709-1711.
18. Chwastiak L, Rosenheck R, Leslie D. Impact of medical comorbidity on the quality of schizophrenia pharmacotherapy in a national VA sample. Med Care. 2006;44:55-61.
19. van Os J, Gilvarry C, Bale R, et al. Diagnostic value of the DSM and ICD categories of psychosis: an evidence-based approach. UK700 Group. Soc Psychiatry Psychiatr Epidemiol. 2000;35:305-311.
20. Jakobsen KD, Frederiksen JN, Hansen T, et al. Reliability of clinical ICD-10 schizophrenia diagnoses. Nord J Psychiatry. 2005;59:209-212.